BioMarin Pharmaceutical Inc.
772 articles with BioMarin Pharmaceutical Inc.
-
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
6/24/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) for its investigational gene therapy, valoctocogene roxaparvovec.
-
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
6/21/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO® (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed.
-
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
6/13/2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of achondroplasia, the most common form of disproportionate short stature.
-
According to recent BioSpace research, diversity and inclusion is an important factor when considering a new employment opportunity for 85% of life sciences community members.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
BioMarin Delays Hemophilia A Therapy Valoctocogene Roxaparvovec Filing as FDA Calls for More Data
5/31/2022
The U.S. FDA has requested some additional data from BioMarin Pharmaceuticals for the BLA it filed for the hemophilia A therapy valoctocogene roxaparvovec. -
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
5/31/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.
-
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
5/5/2022
BioMarin Pharmaceutical Inc. today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
-
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
5/5/2022
BioMarin Pharmaceutical Inc. announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise.
-
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
5/4/2022
BioMarin Pharmaceutical Inc., announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas.
-
The Q1 results for Voxzogo gave BioMarin the confidence to raise its 2022 full-year guidance to between $100 million to $125 million (net product revenue) for the drug.
-
BioMarin Announces Record Revenues in First Quarter 2022
4/27/2022
BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2022.
-
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
-
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
4/13/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.
-
It was a busy week for clinical trial announcements. Here's a look.
-
BioMarin Pharmaceuticals Hemophilia A Data Indicate Potential for "Sustained Bleed Control"
3/18/2022
BioMarin Pharmaceuticals has published positive results in the New England Journal of Medicine from its Phase III clinical trial of valoctocogene roxaparvovec. -
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
3/17/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in the New England Journal of Medicine (NEJM).
-
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2/23/2022
BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter and full-year ended December 31, 2021.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Biomarin indicated that the FDA had requested more data from non-clinical studies to evaluate the theoretical cancer risk to human trial participants. This is likely to take several quarters.